NEW YORK (AP) - Schering-Plough Corp. and OraSure Technologies Inc. said
Monday they agreed to develop and promote a rapid oral hepatitis C virus test
using OraSure's OraQuick blood test.
The agreement expands an existing collaboration for product promotion in
U.S. physicians' office markets, announced last month, to international markets.
Under terms of the deal, Schering-Plough will reimburse OraSure for certain
development costs and will issue payments to OraSure based on certain regulatory
and commercial milestones in international markets.
Financial terms of the deal were not disclosed.
Shares of drug maker Schering-Plough rose 7 cents to $19.84 in morning
trade, while shares of diagnostic test maker OraSure rose 14 cents to $7.75.
Copyright 2007 Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten, or redistributed.
|